Figure 4.
Graphical representations of median overall survival depicting no statistically significant differences between patients the received 1st-line 5-Fluorouracil-based therapies or 1st-line Gemcitabine/nab-Paclitaxel-based therapies within either the lung-only or liver-only cohorts.

(A) Median OS relative to diagnosis of advanced disease for the subset receiving 1st-line 5FU-based SOC vs. 1st-line Gemcitabine/nab-Paclitaxel SOC in the liver-only subset of the mPDAC Analysis Cohort. (B) Median OS relative to diagnosis of advanced disease for the subset receiving 1st-line 5FU-based SOC vs. 1st-line Gemcitabine/nab-Paclitaxel SOC in the lung-only subset of the mPDAC Analysis Cohort.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close